A) Gene expression analysis using the Agilent technologies platform. The Agilent microarrays on which the 60 mers oligonucleotides are printed, allows the detection and hybridization of samples.
B) Preparing and printing customized microarrays. The MicroGrid microarrayers (Genomic Solution) system, with its programmable robotic equipment, gives you a choice of many application modules and is controlled by the Tas Application Suite software.
For more information: Dr. Dimtcho Batchvarov. Director of the FRQS-RCCGF Tenured Professor Departement of Medicine,
Université Laval and CHUQ – Centre de recherche – L’Hôtel-Dieu de Québec
9, rue McMahon, Québec (Québec), Canada, G1R 2J6
Phone : (418) 525-4444, post 15590 Fax : (418) 691-5439
The above information is also readily available on the Hotel-Dieu of Quebec research Center’s website: DNA Microarray Service
The Clinical Research Unit principally conducts phase I and II clinical trials and plays an essential part in the MCTRC/MCETC’s mission to bring cancer research from basic science laboratories into the cancer clinic.
Contact: Ms. Adele Cascini Coordinator, Clinical Research Unit Jewish General Hospital, Rm E-872 Tel: (514) 340-8222 ext 3951 Fax: (514) 340-7574
E-mail: Adele Cascini
The Cell Processing Centre is a clinical-grade, high-sterility isolation facility designed to support early-phase clinical trials of cell-based therapies where the processing of human cells and tissue is required.
Contact: Dr. Nicoletta Eliopoulos, Laboratory Director, Cell Processing Centre Lady Davis Institute, Rm F-13
Tel: (514) 340-8222 ext 2757 Fax: (514) 340-7502
E-mail: Nicoletta Eliopoulos
The Flow Cytometry Unit offers services including cell sorting, supervised acquisition/ analysis, unsupervised acquisition/analysis (for trained Users), training in acquisition and analysis, consulting and project evaluation.
Contact: Mr. Christian Young Manager, Flow Cytometry Unit Lady Davis Institute, Rm E-417
Tel: (514) 340 8222 ext 5172 Fax: (514) 340-8716
E-mail: Christian Young
The High-Performance Computing Facility provides expertise in structure-based drug design.
Contact: Dr. Jian Hui Wu Scientific Director, High Performance Computing Facility Lady Davis Institute, Rm E-536
Tel: (514) 340-8222 ext 2148 Fax: (514) 340-8717
E-mail: Jian Hui Wu
The Peptide Synthesis Laboratory provides a complete spectrum of services that include preparation of peptides on resin, cleavage, purification, and peptide modifications.
Contact: Dr. Uri Saragovi, Scientific Director, Peptide Synthesis Laboratory Lady Davis Institute, Rm E-533
Tel: (514) 340-8222 ext 5055
Fax: (514) 340-8717
E-mail: Uri Saragovi
The Molecular Pathology Facility offers technical expertise related to histopathology and molecular pathology including tissue harvesting, paraffin and frozen tissue sectioning, basic and special stains, immunohistochemistry (IHC), Fluorescent In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH) and Tissue Microarray (TMA) construction and staining.
Contact: Dr. Naciba Benlimame Manager, Research Pathology Facility, Lady Davis Institute, Rm E-433
Tel :(514) 340-8222 ext 3698
Fax: (514) 340-8716
E-mail: Naciba Benlimame
The Translational Proteomics Facility provides access to SELDI-TOF technology for biomarker discovery and proteomic profiling.
Contact: Dr. Adriana Aguilar Manager, Clinical Proteomics Facility, Lady Davis Institute, Rm E-416
Tel: (514) 340-8222 ext 3365 Fax: (514) 340-8716
E-mail: Adriana Aguilar
The Cell Imaging Facility provides expertise in confocal, live cell, FRAP and fluorescent microscopy.
Contact: Christian Young Manager, Cell Imaging Facility, Lady Davis Institute, Rm E-512
Tel: (514) 340-8222 ext 5172 Fax: (514) 340-8716
E-mail: Christian Young
The Translational Physics and Radiobiology Laboratory integrates radiation biology, molecular imaging and medical physics. The laboratory is primarily devoted to the combination of molecular targeted therapies and ionizing radiation with real-time imaging and molecular imaging of both a tumour and its microenvironment.
Contacts: Dr. François DeBlois Medical Physicist Jewish General Hospital, Rm G-18.115
E-mail: François DeBlois
Dr. Thierry Muanza, Radiation Oncologist, Jewish General Hospital, Rm G-002
E-mail : Thierry Muanza
The cytogenetics platform supported by the Maisonneuve-Rosemont Hospital (HMR) and the Institute for Research in Immunology and Cancer (IRIC) provides karyotyping and molecular cytogenetics services to cancer researchers affiliated with the HMR, IRIC, University of Montreal and other Quebec research institutes and universities.
OVERVIEW OF SERVICES
- Cell culture and classical chromosome studies by G-banding.
- FISH on interphase and metaphase cells with different probes, including BACs (probe preparation, labelling, hybridization, validation and analysis); study of chromosome deletions and amplifications.
- Spectral karyotyping on mouse, rat and human samples (chromosome preparation, hybridization and analysis).
- Study of chromosome instability, including breakage/aberration analysis, telomeric associations, aneuploidy assessment and analysis of complex karyotypes.
- Contact: Claude Rondeau
Administrative Coordinator, Maisonneuve-Rosemont Research Centre
E-mail: Claude Rondeau
ATiM is a specialized software developed by the RRCancer in collaboration with CTRnet in order to store research-related data. All fields are coded to specifically respond to research needs. Its features include a web-based platform, support for multiple languages, a modular design which can support the addition of future sites, different sample types, multiple storages etc. ATiM makes it possible to obtain relevant data connected with banked samples including data on demographics, follow-up, treatments and results. It facilitates the management of samples and their products, quality control and monitoring of usage. The program also allows for the annexing of consent forms and pathology reports. ATiM helps researchers select appropriate samples for different research projects and facilitates the writing of scientific reports by pulling specific data from all collected cases within a biobank. Using the program, data can be exported in CVS format for further analyses and all modifications can be tracked, allowing for easy verification of changes made to biobank data.
For additional information, please contact the ATiM manager: Nicolas Luc
The breast cancer research community has many active research projects. These projects depend not only on fixed and frozen tissue but also on “living” biobanks created using xenograft derivatives made with breast cancer tissue. The patient-derived xenograft platform (PDX) of the Goodman Cancer Center concentrates on the creation and analysis of human tumours in animals and as primary tumours cell lines and stromal cell lines associated with clinical samples that are linked to clinical data. This platform includes the administration of standardized therapies and treatments based on targets identified in individual xenografts as well as a comparison with disease progression in the patient and projects examining heterogeneity at a single cell level.
For more information, please contact: Dr. Nicholas Bertos
The hereditary platform contributes to the identification of specific mutations in breast and ovarian cancer. The platform creates a link between MUHC and Segal Center familial cancer cohorts (especially Jewish Ashkenazi families from central and eastern Europe, currently living in Montreal) and CHUM French Canadian cohorts (with Quebec founder mutations). It also promotes the transfer of discoveries regarding genetic predisposition between cohorts. For more information, please contact: Dr. Patricia Tonin
The biobank certification program: The biobank certification program in Quebec was developed by the RRCancer in collaboration with CTRNet in order to help the research community improve the quality and reproducibility of its work by adopting standardized best practices. To this end, this national initiative studied biobank standards across Canada. The program’s objectives are to increase public confidence in biobanks, minimize the risk for research institutes and hospitals, enable the integration of other biobanks, and improve the quality of biological samples. All biobank certification information and educational material can be found on the CTRNet website (www.ctrnet.ca) and on the biobank resource website (www.biobanking.org). For more information, please contact the Quebec certification manager: Manon de Ladurantaye
QBCF-TMAC is a program that regroups together several samples of breast cancer patients from three institutions (CHUM, MUHC and CHUQ). It is assembling a cohort of 2,000 breast cancer samples on tissue micro-arrays (TMA). Please see the attached service description and application form.